CO2020000371A2 - Intermedios útiles para la síntesis de un inhibidor selectivo contra proteín cinasas y procesos para preparar los mismos - Google Patents
Intermedios útiles para la síntesis de un inhibidor selectivo contra proteín cinasas y procesos para preparar los mismosInfo
- Publication number
- CO2020000371A2 CO2020000371A2 CONC2020/0000371A CO2020000371A CO2020000371A2 CO 2020000371 A2 CO2020000371 A2 CO 2020000371A2 CO 2020000371 A CO2020000371 A CO 2020000371A CO 2020000371 A2 CO2020000371 A2 CO 2020000371A2
- Authority
- CO
- Colombia
- Prior art keywords
- processes
- protein kinases
- synthesis
- prepare
- against protein
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 102000001253 Protein Kinase Human genes 0.000 title abstract 3
- 239000000543 intermediate Substances 0.000 title abstract 3
- 108060006633 protein kinase Proteins 0.000 title abstract 3
- 230000015572 biosynthetic process Effects 0.000 title abstract 2
- 238000003786 synthesis reaction Methods 0.000 title abstract 2
- 229940124639 Selective inhibitor Drugs 0.000 title 1
- 102000001301 EGF receptor Human genes 0.000 abstract 1
- 108060006698 EGF receptor Proteins 0.000 abstract 1
- 150000005005 aminopyrimidines Chemical class 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Abstract
La presente invención proporciona intermedios útiles para la síntesis de un derivado de aminopirimidina o sal farmacéuticamente aceptable de este que tiene una actividad inhibitoria selectiva contra proteín cinasas, especialmente contra las proteín cinasas para receptores mutantes del factor de crecimiento epidérmico; y procesos para preparar los mismos. Y también, la presente invención proporciona intermedios novedosos útiles para dicho proceso y procesos para preparar los mismos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20170096226 | 2017-07-28 | ||
PCT/KR2018/008383 WO2019022487A1 (en) | 2017-07-28 | 2018-07-25 | INTERMEDIATES USEFUL FOR THE SYNTHESIS OF A SELECTIVE INHIBITOR TO PROTEIN KINASE AND METHODS FOR THEIR PREPARATION |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2020000371A2 true CO2020000371A2 (es) | 2020-05-05 |
Family
ID=65040643
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2020/0000371A CO2020000371A2 (es) | 2017-07-28 | 2020-01-15 | Intermedios útiles para la síntesis de un inhibidor selectivo contra proteín cinasas y procesos para preparar los mismos |
Country Status (28)
Country | Link |
---|---|
US (1) | US11198684B2 (es) |
EP (1) | EP3658547B1 (es) |
JP (1) | JP7189932B2 (es) |
KR (2) | KR20190013555A (es) |
CN (1) | CN111295381A (es) |
AU (1) | AU2018308164B2 (es) |
BR (1) | BR112020001457A2 (es) |
CA (1) | CA3070070A1 (es) |
CO (1) | CO2020000371A2 (es) |
DK (1) | DK3658547T3 (es) |
EA (1) | EA038078B1 (es) |
ES (1) | ES2959967T3 (es) |
FI (1) | FI3658547T3 (es) |
HR (1) | HRP20231020T1 (es) |
HU (1) | HUE063043T2 (es) |
IL (1) | IL271975B (es) |
LT (1) | LT3658547T (es) |
MA (1) | MA49705A (es) |
NZ (1) | NZ761158A (es) |
PH (1) | PH12020500093A1 (es) |
PL (1) | PL3658547T3 (es) |
PT (1) | PT3658547T (es) |
RS (1) | RS64545B1 (es) |
SA (1) | SA520411115B1 (es) |
SG (1) | SG11201913556SA (es) |
SI (1) | SI3658547T1 (es) |
UA (1) | UA125595C2 (es) |
WO (1) | WO2019022487A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA125317C2 (uk) | 2017-07-28 | 2022-02-16 | Юхан Корпорейшн | Удосконалений спосіб отримання похідних амінопіримідину |
KR20190013554A (ko) * | 2017-07-28 | 2019-02-11 | 주식회사유한양행 | 아미노피리미딘 유도체의 합성에 유용한 신규의 중간체, 이의 제조방법 및 이를 이용한 아미노피리미딘 유도체의 제조방법 |
JOP20210304A1 (ar) | 2019-05-14 | 2023-01-30 | Janssen Biotech Inc | علاجات مركبة باستخدام الأجسام المضادة ثنائية النوعية المضادة لمستقبل عامل نمو البشرة (EGFR)/ مستقبل عامل نمو خلايا الكبد (c-Met) ومثبطات كيناز التيروسين الخاصة بمستقبل عامل نمو البشرة (EGFR) من الجيل الثالث |
US11850248B2 (en) | 2019-05-14 | 2023-12-26 | Yuhan Corporation | Therapies with 3rd generation EGFR tyrosine kinase inhibitors |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0914682B8 (pt) | 2008-06-27 | 2021-05-25 | Avila Therapeutics Inc | compostos de heteroarila e composições compreendendo os referidos compostos |
CA2780892C (en) | 2009-11-13 | 2017-02-14 | Genosco | Kinase inhibitors |
CA2881993C (en) * | 2011-07-27 | 2017-05-09 | Astrazeneca Ab | Substituted 4-methoxy-n3-(pyrimidin-2-yl)benzene-1,3-diamine compounds, and salts thereof |
EP2793880A4 (en) * | 2011-12-23 | 2015-06-24 | Millennium Pharm Inc | HETEROARYLE AND USES THEREOF |
US8871778B2 (en) * | 2012-01-20 | 2014-10-28 | Genosco | Substituted pyrimidine compounds and their use as SYK inhibitors |
US9879008B2 (en) * | 2014-04-14 | 2018-01-30 | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | 2,3,4,6-tetra-substituted benzene-1,5-diamine derivatives, preparation method therefor and medicinal use thereof |
CN105461695B (zh) * | 2014-09-29 | 2018-03-27 | 齐鲁制药有限公司 | 嘧啶或三嗪衍生物及其制备方法和用途 |
CN105524068B (zh) * | 2014-09-30 | 2017-11-24 | 上海海雁医药科技有限公司 | 氮杂双环衍生物、其制法与医药上的用途 |
PT3604294T (pt) * | 2014-10-13 | 2021-07-29 | Yuhan Corp | Compostos e composições para modular atividades da cinase do mutante de egfr |
CN104788427B (zh) * | 2015-02-05 | 2017-05-31 | 上海泓博智源医药股份有限公司 | 3‑(2‑嘧啶氨基)苯基丙烯酰胺类化合物及其应用 |
EP3399968B8 (en) * | 2016-01-07 | 2021-12-01 | Xuanzhu Biopharmaceutical Co., Ltd. | Selective inhibitors of clinically important mutants of the egfr tyrosine kinase |
CN106083736A (zh) * | 2016-06-21 | 2016-11-09 | 郑州泰基鸿诺医药股份有限公司 | 一种嘧啶类化合物、egfr抑制剂及其应用 |
-
2018
- 2018-07-25 BR BR112020001457-5A patent/BR112020001457A2/pt unknown
- 2018-07-25 UA UAA202001302A patent/UA125595C2/uk unknown
- 2018-07-25 HU HUE18838718A patent/HUE063043T2/hu unknown
- 2018-07-25 MA MA049705A patent/MA49705A/fr unknown
- 2018-07-25 PT PT188387187T patent/PT3658547T/pt unknown
- 2018-07-25 WO PCT/KR2018/008383 patent/WO2019022487A1/en active Application Filing
- 2018-07-25 KR KR1020180086378A patent/KR20190013555A/ko active IP Right Grant
- 2018-07-25 LT LTEPPCT/KR2018/008383T patent/LT3658547T/lt unknown
- 2018-07-25 IL IL271975A patent/IL271975B/en unknown
- 2018-07-25 FI FIEP18838718.7T patent/FI3658547T3/fi active
- 2018-07-25 EA EA202090384A patent/EA038078B1/ru unknown
- 2018-07-25 DK DK18838718.7T patent/DK3658547T3/da active
- 2018-07-25 RS RS20230685A patent/RS64545B1/sr unknown
- 2018-07-25 CA CA3070070A patent/CA3070070A1/en active Pending
- 2018-07-25 EP EP18838718.7A patent/EP3658547B1/en active Active
- 2018-07-25 SI SI201830982T patent/SI3658547T1/sl unknown
- 2018-07-25 SG SG11201913556SA patent/SG11201913556SA/en unknown
- 2018-07-25 HR HRP20231020TT patent/HRP20231020T1/hr unknown
- 2018-07-25 AU AU2018308164A patent/AU2018308164B2/en active Active
- 2018-07-25 ES ES18838718T patent/ES2959967T3/es active Active
- 2018-07-25 JP JP2020504208A patent/JP7189932B2/ja active Active
- 2018-07-25 CN CN201880048980.9A patent/CN111295381A/zh active Pending
- 2018-07-25 PL PL18838718.7T patent/PL3658547T3/pl unknown
- 2018-07-25 NZ NZ761158A patent/NZ761158A/en not_active IP Right Cessation
- 2018-07-25 US US16/633,756 patent/US11198684B2/en active Active
-
2020
- 2020-01-14 PH PH12020500093A patent/PH12020500093A1/en unknown
- 2020-01-15 CO CONC2020/0000371A patent/CO2020000371A2/es unknown
- 2020-01-22 SA SA520411115A patent/SA520411115B1/ar unknown
-
2023
- 2023-09-21 KR KR1020230126377A patent/KR20230137282A/ko not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2020000371A2 (es) | Intermedios útiles para la síntesis de un inhibidor selectivo contra proteín cinasas y procesos para preparar los mismos | |
CO2019011809A2 (es) | Compuestos de imidazo-piperidina fusionada como inhibidores de jak | |
AR113803A1 (es) | Compuesto de pirimidina como inhibidor de jak quinasas | |
CO2017012267A2 (es) | Compuestos de naftiridina como inhibidores de la quinasa jak | |
CO2018011408A2 (es) | Compuestos de pirimidina como inhibidores de la quinasa jak | |
CL2020000886A1 (es) | Derivados de 1-benzil-2-imino-4-fenil-5-oxoimidazolidina como inhibidores de la proteasa del vih. | |
CO2021002977A2 (es) | Dimetilaminoazetidinaminas como inhibidores de jak | |
BR112021007788A8 (pt) | Composto inibidor de jak 2-azabiciclo hexano | |
PH12017550004B1 (en) | Heterocyclic derivatives and use thereof | |
CO2020000374A2 (es) | Proceso mejorado para preparar derivados de aminopirimidina | |
EA202193015A1 (ru) | Ингибиторы cdk | |
CO2019005514A2 (es) | Derivado de pirido[3,4–d]pirimidina y su sal farmacéuticamente aceptable | |
UY38233A (es) | Agentes inhibidores para la tirosina cinasa de bruton | |
CO2021007172A2 (es) | Sales cristalinas de un inhibidor de calicreína plasmática | |
CL2021000580A1 (es) | Uso de inhibidores de la caseina quinasa 1 para el tratamiento de enfermedades vasculares. | |
CO2020000595A2 (es) | Intermedios novedosos útiles para la síntesis de derivados de aminopirimidina, proceso para prepararlos, y proceso para preparar derivados de aminopirimidina usando estos | |
CL2019001804A1 (es) | Activador de nrf2. | |
EA201990313A1 (ru) | Производное триазолопиразинона, пригодное в качестве ингибитора фдэ1 человека | |
WO2018075598A8 (en) | SYNTHESIS OF EZH2 INHIBITORS | |
CY1123076T1 (el) | Ενωσεις βενζο-ν-υδροξυ αμιδιου που εχουν αντικαρκινικη δραστikothta | |
CO2019012594A2 (es) | Proceso para la preparación de enantiómeros de pirlindol y sus sales | |
EA201992258A1 (ru) | Способы изготовления нирапариба |